Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines

• Published in: Malaria journal 2021-01, Vol.20 (1), p.62-62, Article 62
• Main Authors: Al Khaja, Khalid A J, Sequeira, Reginald P
• Format: Article
• Language: English
• Subjects: Anemia; Antimalarial agents; Antimalarials; Artemether; Artemisinin; Artesunate; Binding sites; Chloroquine; Clindamycin; Complications; Cotrimoxazole; Disease prophylaxis; Dosage and administration; Drug dosages; Drug therapy; Drugs; Erythrocytes; Evaluation; Fetuses; Folic acid; Government; Guidelines; HIV; Human diseases; Human immunodeficiency virus; Infections; Intravenous administration; Malaria; National guidelines; Parasites; Plasmodium falciparum; Practice guidelines (Medicine); Pregnancy; Pregnant women; Prenatal care; Prevention; Prophylaxis; Pyrimethamine; Quinine; Recent trends; Regions; Review; Reviews; Stillbirth; Sulfadoxine; Treatment guidelines; Vector-borne diseases; WHO; Women; Womens health
• ISSN: 1475-2875; 1475-2875
• DOI: 10.1186/s12936-020-03565-2

Malaria caused by Plasmodium falciparum in pregnancy can result in adverse maternal and fetal sequelae. This review evaluated the adherence of the national guidelines drawn from World Health Organization (WHO) regions, Africa, Eastern Mediterranean, Southeast Asia, and Western Pacific, to the WHO recommendations on drug treatment and prevention of chloroquine-resistant falciparum malaria in pregnant women. Thirty-five updated national guidelines and the President's Malaria Initiative (PMI), available in English language, were reviewed. The primary outcome measures were the first-line anti-malarial treatment protocols adopted by national guidelines for uncomplicated and complicated falciparum malaria infections in early (first) and late (second and third) trimesters of pregnancy. The strategy of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) was also addressed. This review evaluated the treatment and prevention of falciparum malaria in pregnancy in 35 national guidelines/PMI-Malaria Operational Plans (MOP) reports out of 95 malaria-endemic countries. Of the 35 national guidelines, 10 (28.6%) recommend oral quinine plus clindamycin as first-line treatment for uncomplicated malaria in the first trimester. As the first-line option, artemether-lumefantrine, an artemisinin-based combination therapy, is adopted by 26 (74.3%) of the guidelines for treating uncomplicated or complicated malaria in the second and third trimesters. Intravenous artesunate is approved by 18 (51.4%) and 31 (88.6%) guidelines for treating complicated malaria during early and late pregnancy, respectively. Of the 23 national guidelines that recommend IPTp-SP strategy, 8 (34.8%) are not explicit about directly observed therapy requirements, and three-quarters, 17 (73.9%), do not specify contra-indication of SP in human immunodeficiency virus (HIV)-infected pregnant women receiving cotrimoxazole prophylaxis. Most of the guidelines (18/23; 78.3%) state the recommended folic acid dose. Several national guidelines and PMI reports require update revisions to harmonize with international guidelines and emergent trends in managing falciparum malaria in pregnancy. National guidelines and those of donor agencies should comply with those of WHO guideline recommendations although local conditions and delayed guideline updates may call for deviations from WHO evidence-based guidelines.